The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson, MD, University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the current state of frontline management of Richter’s transformation, noting that the field agrees the standard of care is inadequate and outcomes with chemoimmunotherapy are poor due to the disease’s intrinsic chemoresistance. Dr Thompson highlights that clinical trials have shown promising results with additions to chemoimmunotherapy, and combinations of small molecules with checkpoint inhibitors, as well as the emerging use of bispecific antibodies. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
